Optimal dosing of mycophenolate mofetil (MMF) is necessary to delay hepatitis C recurrence (HEP CR) in liver transplant recipients.

被引：0
|
作者：
Fasola, CG [1 ]
Netto, GJ [1 ]
Christensen, LL [1 ]
Sanchez, EQ [1 ]
Molmenti, EM [1 ]
Gonwa, TA [1 ]
Goldstein, RM [1 ]
Levy, MF [1 ]
Klintmalm, GB [1 ]
机构：
[1] Baylor Univ, Med Ctr, Dallas, TX USA
来源：
HEPATOLOGY | 2001年 / 34卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1869
引用
收藏
页码：639A / 639A
页数：1
相关论文
共 50 条
  • [41] The Expression of Genes Related to B Cells Are Associated to a Successful Conversion from Calcineurin Inhibitor (CNI) Based Immunosupresion to Mycophenolate Mofetil (MMF) Monotherapy in Liver Transplant Recipients.
    Norero, Blanca
    Serrano, Carolina
    Maria Perez, Rosa
    Duarte, Ignacio
    Arrese, Marco
    Soza, Alejandro
    Jarufe, Nicolas
    Martinez, Jorge
    Francisco Guerra, Juan
    Benitez, Carlos
    [J]. LIVER TRANSPLANTATION, 2014, 20 : S105 - S105
  • [42] Sirolismus in post hepatitis C virus (HCV) liver transplant recipients.
    Marrero, R
    Neff, GW
    Montalbano, M
    Nery, J
    Weppler, D
    Schiff, ER
    Tzakis, AG
    [J]. HEPATOLOGY, 2002, 36 (04) : 664A - 664A
  • [43] Predictors of graft outcome in hepatitis C positive liver transplant recipients.
    Horton, PJ
    Barkun, J
    Rochon, C
    Fernandez, M
    Metrakos, P
    Tchervenkov, J
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 177 - 177
  • [44] Mycophenolate Mofetil at the Time of Transplant Is an Important Independent Predictor of Early Hepatitis C Recurrence.
    Weimert, Nicole A.
    Taber, David J.
    Scheffert, Jenna L.
    Patel, Neha
    Dunn, Brianne D.
    Hughes, Michael G.
    Baliga, Prabhakar K.
    Chavin, Kenneth D.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 524 - 524
  • [45] Mycophenolate mofetil (MMF) monotherapy improves renal dysfunction in orthotopic liver transplant (OLT) recipients without increased risk of rejection
    Raimondo, ML
    Dagher, L
    Papatheodoridis, G
    Gunsar, F
    Turchi, V
    Rolles, K
    Davidson, B
    Patch, D
    Burroughs, A
    [J]. JOURNAL OF HEPATOLOGY, 2002, 36 : 193 - 193
  • [46] A prospective randomised controlled trial of mycophenolate mofetil (MMF) as primary immunosuppression in paediatric liver transplant recipients - An interim analysis.
    Bansal, S
    Verma, A
    Taylor, R
    Cheeseman, P
    Samyn, M
    Heaton, N
    Rela, M
    Mieli-Vergani, G
    Dhawan, A
    [J]. HEPATOLOGY, 2004, 40 (04) : 476A - 476A
  • [47] Post-transplant diabetes mellitus and recurrent graft hepatitis in hepatitis C(+) liver transplant recipients.
    Baid, S
    Cosimi, AB
    Farrell, M
    Rubin, N
    Chung, R
    Feng, S
    Pascual, M
    [J]. TRANSPLANTATION, 2000, 69 (08) : S267 - S267
  • [48] Monitoring mycophenolic acid (MPA) plasma levels may benefit the management of liver transplant recipients treated with mycophenolate mofetil (MMF).
    Brown, NW
    Gonde, C
    Adams, J
    Tredger, JM
    [J]. THERAPEUTIC DRUG MONITORING, 2003, 25 (04) : 513 - 513
  • [49] Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation
    Kornberg, A
    Küpper, B
    Tannapfel, A
    Hommann, M
    Scheele, J
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2005, 5 (01) : 107 - 115
  • [50] Chronic rejection after interferon therapy in hepatitis C liver transplant recipients.
    Landry, GM
    Feng, S
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 375 - 375
12345